- Home
- SLN vs CLLS Comparison
SLN vs CLLS Comparison
Compare SLN & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLN
- CLLS
- Stock Information
- Founded
- SLN 1994
- CLLS 1999
- Country
- SLN United Kingdom
- CLLS France
- Employees
- SLN N/A
- CLLS N/A
- Industry
- SLN Biotechnology: Pharmaceutical Preparations
- CLLS Biotechnology: Pharmaceutical Preparations
- Sector
- SLN Health Care
- CLLS Health Care
- Exchange
- SLN Nasdaq
- CLLS Nasdaq
- Market Cap
- SLN 268.8M
- CLLS 299.0M
- IPO Year
- SLN N/A
- CLLS 2007
- Fundamental
- Price
- SLN $6.59
- CLLS $4.52
- Analyst Decision
- SLN Buy
- CLLS Buy
- Analyst Count
- SLN 6
- CLLS 1
- Target Price
- SLN $39.67
- CLLS $4.00
- AVG Volume (30 Days)
- SLN 115.5K
- CLLS 225.2K
- Earning Date
- SLN 11-13-2025
- CLLS 11-03-2025
- Dividend Yield
- SLN N/A
- CLLS N/A
- EPS Growth
- SLN N/A
- CLLS N/A
- EPS
- SLN N/A
- CLLS N/A
- Revenue
- SLN $27,169,000.00
- CLLS $63,438,000.00
- Revenue This Year
- SLN N/A
- CLLS N/A
- Revenue Next Year
- SLN N/A
- CLLS $66.76
- P/E Ratio
- SLN N/A
- CLLS N/A
- Revenue Growth
- SLN 22.28
- CLLS 223.09
- 52 Week Low
- SLN $1.97
- CLLS $1.10
- 52 Week High
- SLN $19.36
- CLLS $5.48
- Technical
- Relative Strength Index (RSI)
- SLN 69.56
- CLLS 68.24
- Support Level
- SLN $5.00
- CLLS $3.84
- Resistance Level
- SLN $5.83
- CLLS $4.55
- Average True Range (ATR)
- SLN 0.41
- CLLS 0.39
- MACD
- SLN 0.16
- CLLS 0.07
- Stochastic Oscillator
- SLN 93.42
- CLLS 67.90
About SLN Silence Therapeutics Plc American Depository Share
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.